Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 2/20 | 0.61 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.61 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.61 |
| ▸ | PIM1 | P11309 | 1/20 | 0.61 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.61 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.61 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.61 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.61 |
| ▸ | LTK | P29376 | 1/20 | 0.53 |
| ▸ | MST1R | Q04912 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 5/20 | 0.46 |
| ▸ | KDR | P35968 | 4/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.44 |
| ▸ | PARP11 | Q9NR21 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31303452 | 1.00 | CDK5 (0.61) | CDK5DYRK1ACLK4PIM1CSNK1A1 | |
| SCHEMBL797996 | 0.81 | PARP1 (0.64) | PARP1PARP10PARP11MAPT | |
| SCHEMBL30233773 | 0.81 | PARP1 (0.64) | PARP1PARP10PARP11MAPT | |
| SCHEMBL6297545 | 0.78 | PARP1 (0.70) | CDK5DYRK1ACLK4PIM1CSNK1A1 | |
| SCHEMBL29532218 | 0.78 | PARP1 (0.70) | CDK5DYRK1ACLK4PIM1CSNK1A1 | |
| SCHEMBL24148319 | 0.76 | CDK5 (0.61) | CDK5DYRK1ACLK4PIM1CSNK1A1 | |
| SCHEMBL1333810 | 0.76 | CLK4 (1.00) | CDK5DYRK1ACLK4PIM1CSNK1A1 | |
| SCHEMBL11450232 | 0.76 | CDK5 (0.47) | CDK5DYRK1ACLK4PIM1CSNK1A1 | |
| SCHEMBL1078443 | 0.76 | CDK5 (0.61) | CDK5DYRK1ACLK4PIM1CSNK1A1 | |
| SCHEMBL9475196 | 0.76 | PARP1 (0.68) | CDK5DYRK1ACLK4PIM1CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144881-A1 | HPK1 TARGETING COMPOUNDS AND USES THEREOF | ARVINAS OPERATIONS, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| WO-2025096666-A1 | SOLID FORMS OF HPK1 ANTAGONISTS | Nimbus Saturn, Inc. (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-119874700-A | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2025-04-25 | — | — | CN | disclosed |
| US-12215105-B2 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20250011331-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2025-01-09 | — | — | US | disclosed |
| CN-114945366-B | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20240199603-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-06-20 | — | — | US | disclosed |
| EP-4380565-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-118119628-A | HPK1 kinase inhibitor and preparation method and application thereof | 珠海宇繁生物科技有限责任公司 | 2024-05-31 | — | — | CN | disclosed |
| US-7652020-B2 | novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction | SCHERING CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| WO-2009014637-A2 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2009-01-29 | — | — | WO | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| WO-2007064749-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND MICROBIAL DISEASES | SCHERING CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
| WO-2005121130-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011331-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | CDK5 934/4885DYRK1A 860/4885CLK4 198/4885 |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, ADAMTS1, ADAM33 | CDK5 3377/4885DYRK1A 4347/4885CLK4 3422/4885 |
| US-20260144881-A1 | HPK1 TARGETING COMPOUNDS AND USES THEREOF | SGK1, PBK, SGK3 | CDK5 1310/4885DYRK1A 663/4885CLK4 228/4885 |
| US-20240199603-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | CDK5 934/4885DYRK1A 860/4885CLK4 198/4885 |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | CDK5 2680/4885DYRK1A 4285/4885CLK4 3157/4885 |
| US-12215105-B2 | HPK1 antagonists and uses thereof | PDXK, HIPK1, PCK1 | CDK5 934/4885DYRK1A 860/4885CLK4 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.